PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
MEMORANDUM
June 20, 2023
FROM: Miriam Calloway, Partner, and Christopher Aiken, Senior Associate Calderwood & Harkness LLP One Federal Street, 30th Floor Boston, MA 02110
TO: Patricia Yamamoto, General Counsel, and Derek Huang, Chief Compliance Officer Arbor Health Technologies Inc. 200 Concord Avenue, Suite 400 Cambridge, MA 02138
RE: Evaluation of Voluntary Self-Disclosure to the Office of Inspector General Under the OIG Self-Disclosure Protocol — Anti-Kickback Statute Compliance Issues Identified in Self-Assessment
Matter No.: 1010-00003
This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared by Calderwood & Harkness LLP at the direction of Arbor Health Technologies Inc. ("AHT") for the purpose of providing legal advice. This memorandum and its contents are protected from disclosure by the attorney-client privilege, the work product doctrine, and all other applicable privileges and protections. No portion of this memorandum should be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP and AHT General Counsel. Voluntary disclosure of this memorandum or its contents to any third party may result in a waiver of applicable privileges.
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to evaluate whether any violations of the federal Anti-Kickback Statute ("AKS"), 42 U.S.C. § 1320a-7b(b), identified during the Calderwood & Harkness self-assessment engagement (opened January 30, 2023) warrant voluntary self-disclosure by Arbor Health Technologies Inc. ("AHT") to the United States Department of Health and Human Services Office of Inspector General ("OIG") under the OIG Self-Disclosure Protocol ("SDP"). This memorandum sets forth the relevant legal framework, analyzes the specific arrangements giving rise to the most significant AKS risk, estimates the potential financial exposure under various enforcement scenarios, weighs the factors for and against filing an SDP submission, and provides a recommendation to AHT management and the Board Compliance Committee.
The self-assessment engagement was triggered by concerns raised during a board-level compliance committee review following AHT's acquisition of Lakeview Medical Associates, P.C. ("Lakeview"), which closed on August 15, 2022, as an asset purchase transaction valued at $11.4 million. The engagement was formally authorized by AHT Board Resolution No. 2023-01-004, adopted on January 24, 2023, following the receipt and review of a compliance gap assessment report prepared by Grayson Whitaker & Associates LLP (report reference GW-AHT-2022-Final, dated December 12, 2022). The Grayson Whitaker report identified seventeen (17) high-risk arrangements and twenty-three (23) moderate-risk arrangements across AHT's provider network that required further legal analysis for compliance with federal and state healthcare fraud and abuse laws, including the AKS and the Stark Law.
Following a comprehensive review of the arrangements identified in the Grayson Whitaker report, supplemented by additional document review, management interviews, and preliminary fair market value ("FMV") findings from Northbridge Valuation Advisors LLC, Calderwood & Harkness has identified three categories of arrangements that pose the highest AKS risk and that are most relevant to the OIG SDP filing decision:
1. Meridian Diagnostics LLC Per-Scan Facility Access Fee. A services agreement under which Meridian Diagnostics LLC pays AHT a per-scan facility access fee of $185 per scan for use of AHT clinic space in Connecticut, resulting in $777,000 in fee revenue to AHT in FY2022 alongside approximately $2.8 million in referrals from AHT physicians to Meridian. The per-scan fee structure varies directly with the volume of scans performed and does not satisfy any applicable AKS safe harbor.
2. Pinnacle Laboratory Services Inc. No-Cost Electronic Lab Interface and CME Sponsorship. A preferred laboratory agreement under which Pinnacle provides AHT with a no-cost electronic laboratory interface (estimated market value: $120,000 per year) and sponsored four continuing medical education ("CME") events for AHT physicians totaling $86,000 in FY2022, in the context of approximately $1.65 million in annual referral volume from AHT to Pinnacle. This arrangement is further complicated by Dr. Karen Ellsworth's 4.2% passive equity interest in Pinnacle; Dr. Ellsworth is the spouse of AHT Chief Executive Officer Dr. Nathan Ellsworth.
3. Above-FMV Medical Director Compensation (38 Arrangements). AHT maintains thirty-eight (38) independent contractor / medical director arrangements across its 23-clinic network, with aggregate annual compensation of $1.92 million and an effective average hourly rate of $501.28 per hour — a figure that exceeds the 90th percentile for multiple physician specialties based on MGMA and SullivanCotter benchmark data, as confirmed by preliminary findings from Northbridge Valuation Advisors LLC.
Summary Conclusion. Based on the analysis set forth in this memorandum, Calderwood & Harkness recommends that AHT not file a voluntary self-disclosure under the OIG Self-Disclosure Protocol at this time, subject to the timely completion of all remediation measures described herein and in the Final Report and Remediation Roadmap. This recommendation is based on our assessment that the identified arrangements are more appropriately characterized as structural compliance deficiencies amenable to prospective remediation rather than conduct involving actual corrupt intent or a clear scheme to pay or receive kickbacks within the meaning of the AKS. The risk profile, while significant, is mitigated by the following considerations: (a) the absence of any prior enforcement actions against AHT; (b) the absence of any existing Corporate Integrity Agreement; (c) the proactive and voluntary nature of AHT's self-assessment, which was initiated at the board level without any external trigger such as a government inquiry or whistleblower complaint; and (d) AHT's demonstrated commitment to prompt restructuring, remediation, and enhanced compliance infrastructure.
This recommendation is, however, expressly contingent on the conditions and caveats set forth in Section IX.B below, and should be reassessed in the event of any material change in circumstances, including but not limited to the receipt of any government inquiry, subpoena, civil investigative demand, or notification of a qui tam action.
This memorandum should be read in conjunction with the companion CMS Stark Self-Referral Disclosure Protocol ("SRDP") Evaluation Memorandum, as certain of the arrangements analyzed herein raise overlapping Stark Law issues that are analyzed separately in that companion memorandum. The Stark Law analysis proceeds under a different legal framework — strict liability without an intent requirement — and accordingly involves a distinct disclosure calculus.
II. Background
A. AHT Overview
Arbor Health Technologies Inc. ("AHT") is a Delaware corporation headquartered at 200 Concord Avenue, Suite 400, Cambridge, Massachusetts 02138. AHT operates a network of twenty-three (23) outpatient clinics, branded as "Arbor Health Clinics," across four states in New England. The clinic distribution is as follows: fourteen (14) clinics in Massachusetts, four (4) clinics in Connecticut, three (3) clinics in Rhode Island, and two (2) clinics in New Hampshire. The clinics provide a range of healthcare services, including primary care, specialty care in cardiology, orthopedics, and gastroenterology, and ancillary services including in-office laboratory testing, diagnostic imaging, and physical therapy.
In addition to its clinical operations, AHT owns and operates a proprietary electronic health record ("EHR") and practice management software-as-a-service ("SaaS") platform known as ArborConnect. ArborConnect is currently licensed to forty-two (42) external physician practices, generating approximately $8.9 million in annual subscription revenue. The ArborConnect platform is relevant to the analysis herein because it is the platform into which the Pinnacle Laboratory no-cost electronic interface is integrated.
AHT's financial profile is summarized as follows. For fiscal year 2022, AHT reported net revenue of approximately $214.3 million. Of this total, approximately 61%, or $130.7 million, was derived from Medicare and Medicaid reimbursement. The remaining approximately 39%, or $83.6 million, was attributable to commercial payer revenue. The concentration of AHT's revenue in federal healthcare programs is a critical factor in the AKS risk analysis and the OIG SDP filing calculus, as it establishes the magnitude of the government's potential loss argument and the potential consequences of exclusion from federal healthcare programs.
AHT employs a clinical and administrative workforce of approximately 1,340 individuals. The physician workforce consists of 147 W-2 employed physicians and 38 physicians retained as independent contractors or medical directors. The 38 independent contractor / medical director arrangements are a principal focus of the analysis herein.
AHT is a portfolio company of Ridgeline Capital Partners Fund IV, L.P. ("Ridgeline Fund IV"), which acquired a 72% equity stake in AHT in January 2021 for approximately $185 million. Ridgeline Fund IV is managed by Ridgeline Capital Advisors LLC, located at 400 Steamboat Road, Suite 300, Greenwich, Connecticut 06830. Ridgeline's board designees are Claudia Sorrento, Managing Director, and Marcus Whitmore, Principal, of Ridgeline Capital Advisors LLC. The private equity ownership structure is relevant to this analysis for several reasons: (i) the Ridgeline acquisition in January 2021 is approximately contemporaneous with several of the arrangements under review; (ii) Ridgeline's anticipated late-2024 exit or sale process could be materially complicated by a pending OIG SDP submission; and (iii) the PE sponsor relationship may be relevant to the OIG's assessment of AHT's compliance culture and governance.
AHT's senior leadership relevant to this engagement includes Dr. Nathan Ellsworth, Chief Executive Officer; Patricia Yamamoto, General Counsel; and Derek Huang, Chief Compliance Officer. AHT's Employer Identification Number is 84-3291057. AHT's National Provider Identifier is 1497253810, and its lead Provider Transaction Access Number ("PTAN") is 27MA4891.
It is significant to note that AHT has no prior enforcement actions of any kind, no existing Corporate Integrity Agreement, and no pending OIG Advisory Opinion requests. AHT's Compliance Committee Charter was originally adopted on April 15, 2021, and was most recently amended on October 30, 2022, in connection with the post-acquisition compliance integration of Lakeview Medical Associates.
B. Engagement Context
The engagement giving rise to this memorandum proceeded through several phases. In October 2022, AHT retained Grayson Whitaker & Associates LLP ("Grayson Whitaker"), a healthcare regulatory consulting firm located at 4700 River Road, Suite 220, Bethesda, Maryland 20816, to conduct an initial internal compliance gap assessment of AHT's physician arrangements, vendor relationships, and referral patterns. The engagement principal at Grayson Whitaker was Carolyn Fitch. The Grayson Whitaker engagement was prompted by AHT management's recognition, in the wake of the Lakeview acquisition, that the combined entity's arrangement portfolio had grown significantly and had not been subject to a comprehensive compliance review since the Ridgeline acquisition in January 2021.
On December 12, 2022, Grayson Whitaker delivered its final report (reference: GW-AHT-2022-Final). The report identified seventeen (17) high-risk arrangements and twenty-three (23) moderate-risk arrangements across AHT's provider network. The report recommended that AHT engage specialized healthcare regulatory counsel to conduct a detailed legal analysis of the identified arrangements under the AKS, the Stark Law, and related federal and state healthcare fraud and abuse statutes, and to evaluate whether voluntary self-disclosure to the OIG and/or CMS was warranted.
Upon receipt and review of the Grayson Whitaker report, the AHT Board of Directors, acting through its Compliance Committee, adopted Board Resolution No. 2023-01-004 on January 24, 2023. The Resolution authorized the engagement of Calderwood & Harkness LLP to conduct a comprehensive legal review of the identified arrangements, to evaluate AHT's exposure under the AKS and the Stark Law, and to advise on the advisability of voluntary self-disclosure under the OIG SDP and the CMS SRDP. Calderwood & Harkness's engagement was formally opened on January 30, 2023, and was assigned Matter No. 1010-00003.
In February 2023, at Calderwood & Harkness's recommendation, AHT retained Northbridge Valuation Advisors LLC ("Northbridge"), located at 1600 Market Street, Suite 2800, Philadelphia, Pennsylvania 19103, to provide independent fair market value ("FMV") opinions for AHT's physician compensation arrangements. The engagement is being led by Managing Director Sandra Kilpatrick. Northbridge's preliminary findings, referenced throughout this memorandum, are based on standard valuation methodologies including MGMA and SullivanCotter benchmark data, market-based comparable transaction analysis, and income-based approaches where appropriate. Final Northbridge opinions are expected by approximately July 31, 2023.
Separately, AHT's external auditor, Halsted Accounting Group LLP ("Halsted"), located at 225 Dyer Street, Suite 800, Providence, Rhode Island 02903, had flagged in its FY2022 management letter that certain physician compensation arrangements may require FMV substantiation. The engagement partner at Halsted is Ronald Desmond. The Halsted management letter observation, while not a formal audit finding, provided an additional impetus for the comprehensive review undertaken in this engagement.
Westbrook Hale LLP ("Westbrook Hale"), located at 100 Summer Street, Suite 2200, Boston, Massachusetts 02110, serves as AHT's general outside corporate counsel. Partner Elena Marchetti of Westbrook Hale led the legal aspects of the Lakeview acquisition. Westbrook Hale has deferred to Calderwood & Harkness on all healthcare regulatory matters arising from this engagement, consistent with its acknowledgment that specialized healthcare regulatory expertise is required for the issues under review.
C. Scope of this Memorandum
This memorandum focuses exclusively on AHT's exposure under the federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), and on the question of whether a voluntary self-disclosure to the OIG under the SDP is warranted based on the arrangements identified in the self-assessment. The analysis of AHT's exposure under the Stark Law (42 U.S.C. § 1395nn) and the question of whether a voluntary self-disclosure to CMS under the Self-Referral Disclosure Protocol ("SRDP") is warranted is addressed in a separate, companion CMS SRDP Evaluation Memorandum.
The substantive analysis in this memorandum concentrates on the three categories of arrangements that pose the highest AKS risk — the Meridian Diagnostics per-scan facility access fee, the Pinnacle Laboratory no-cost electronic interface and CME sponsorship (including Dr. Karen Ellsworth's equity interest), and the above-FMV medical director compensation across 38 arrangements — followed by a summary assessment of additional moderate-risk arrangements. The memorandum concludes with an overall recommendation and the conditions under which that recommendation should be reassessed.
This memorandum should be read in conjunction with the following companion engagement deliverables, which provide more granular analysis of specific arrangements and issues:
• AKS Compliance Assessment Memorandum (comprehensive arrangement-by-arrangement AKS analysis)
• Meridian Diagnostics LLC Detailed AKS/Stark Analysis
• Pinnacle Laboratory Services Inc. Detailed AKS/Stark Analysis
• Medical Director Compensation FMV and Commercial Reasonableness Analysis
• ConnectiCare Physicians Network Indirect Compensation Analysis
• Master Arrangement Inventory & Risk Scoring Matrix
• CMS SRDP Evaluation Memorandum
III. OIG Self-Disclosure Protocol — Legal Framework
A. Overview of the OIG SDP
The OIG Self-Disclosure Protocol was established by the OIG to provide healthcare providers, suppliers, and other persons subject to the OIG's civil monetary penalty and program exclusion authorities with a mechanism to voluntarily identify, disclose, and resolve potential instances of fraud involving federal healthcare programs, including conduct that may violate the AKS. The SDP reflects the OIG's longstanding position that healthcare entities that proactively identify and disclose potential violations should receive more favorable treatment than those whose misconduct is discovered through government-initiated investigations, audits, or whistleblower actions.
The SDP was originally published in the Federal Register at 63 Fed. Reg. 58399 (October 30, 1998) and has been updated periodically, including a significant revision published on April 17, 2013, which streamlined the submission process and provided additional guidance regarding the types of matters appropriate for SDP resolution. The OIG has also issued various guidance documents, open letters, and advisory materials further elaborating on the SDP's scope, procedures, and expected outcomes.
The SDP is designed for matters that potentially violate federal criminal, civil, or administrative laws for which penalties or exclusion are authorized, including but not limited to violations of the AKS, the Civil Monetary Penalties Law ("CMPL"), and other federal healthcare fraud statutes. The SDP is available when the disclosing entity has actual knowledge of, or reason to know about, the potential misconduct. Importantly, the SDP is generally appropriate for matters that the OIG can resolve directly; matters that appear to involve significant criminal conduct may be referred by the OIG to the Department of Justice ("DOJ") for criminal investigation and prosecution.
B. OIG SDP Submission Requirements
A complete SDP submission must include a detailed written narrative and supporting documentation sufficient to allow the OIG to evaluate the nature and scope of the disclosed conduct. Specifically, the OIG requires the following elements in an SDP submission:
1. A detailed description of the conduct giving rise to the disclosure, including the nature of the arrangement(s), the parties involved, and the manner in which the conduct potentially violates applicable federal law.
2. The time period during which the conduct occurred, including the inception date of the arrangement(s) and the date on which the conduct was identified or terminated.
3. The names, titles, and roles of all individuals and entities involved in the conduct, including the disclosing entity, any co-participants, and any individuals who authorized, directed, or were aware of the conduct.
4. A detailed explanation of how the matter was discovered, including whether the discovery resulted from an internal audit, compliance review, whistleblower complaint, or other mechanism.
5. A comprehensive description of all corrective actions taken or planned, including the termination or restructuring of the arrangement(s), changes to policies and procedures, training initiatives, and any personnel actions.
6. A financial analysis estimating the damages or losses to federal healthcare programs resulting from the disclosed conduct. This analysis should include, at a minimum, the total remuneration paid or received in connection with the arrangement(s), the total volume and value of federal healthcare program claims associated with the arrangement(s), and the entity's calculation of the estimated damages.
7. All supporting documentation, including copies of relevant agreements, financial records, organizational charts, correspondence, and any internal or external reports related to the disclosed conduct.
The OIG has emphasized that SDP submissions should be thorough, candid, and complete. Incomplete or misleading submissions may result in adverse consequences, including the OIG's decision to refer the matter to DOJ, to initiate its own investigation, or to decline to resolve the matter through the SDP process.
C. Benefits of Voluntary Self-Disclosure
Voluntary self-disclosure under the OIG SDP offers several potential benefits to disclosing entities. These benefits must be weighed against the risks and costs of filing, as discussed in Section III.D below.
First, the OIG has generally taken the approach of resolving SDP matters at a settlement amount of 1.5 times single damages (i.e., 1.5 times the amount of the remuneration at issue or the government's loss), rather than the treble damages that are available under the False Claims Act or the full per-violation penalties available under the CMPL. This reduced penalty framework represents a potentially significant financial benefit to disclosing entities, particularly where the total remuneration or government loss is substantial.
Second, voluntary self-disclosure may enable the disclosing entity to avoid permissive exclusion from federal healthcare programs under 42 U.S.C. § 1320a-7(b)(7). Exclusion from Medicare and Medicaid would be an existential threat to AHT given that 61% of its revenue derives from these programs. The OIG has indicated that it is less likely to pursue exclusion against entities that voluntarily disclose and promptly remediate potential violations.
Third, filing an SDP submission demonstrates good faith compliance efforts and a commitment to operating within the law. This demonstration of good faith can be valuable not only in the context of the SDP resolution itself, but also in any subsequent enforcement action, audit, or compliance review by federal or state authorities.
Fourth, in the event that a qui tam action or government investigation is subsequently initiated, the disclosing entity's prior voluntary disclosure may provide significant mitigating credit in the resolution of such action. Courts and enforcement authorities have recognized that voluntary disclosure prior to government contact is indicative of a genuine commitment to compliance and is entitled to meaningful weight in penalty calculations.
Fifth, SDP resolutions generally involve more favorable settlement terms than government-initiated enforcement actions, including the avoidance of mandatory Corporate Integrity Agreements in many cases and more limited prospective compliance obligations.
D. Risks and Costs of Filing
The decision to file an SDP submission is not without significant risks and costs, which must be carefully weighed against the potential benefits.
First, the filing of an SDP submission constitutes an acknowledgment that potential misconduct has occurred. While the SDP process is intended to be cooperative and confidential, the information provided by the disclosing entity in an SDP submission may be used by the OIG or DOJ in enforcement proceedings if the SDP process does not result in a mutually acceptable resolution. The disclosing entity effectively provides the government with a roadmap of its potential violations, which could be used to support a civil, criminal, or administrative enforcement action.
Second, the preparation of a comprehensive SDP submission involves significant costs, including attorney fees, consultant fees, and internal management time. Based on Calderwood & Harkness's experience with similar submissions, the estimated cost of preparing a complete SDP submission for the arrangements identified herein is approximately $200,000 to $400,000 in additional legal fees, exclusive of the costs of any subsequent negotiation with the OIG.
Third, the OIG retains the discretion to refer matters disclosed through the SDP to DOJ for criminal prosecution or False Claims Act investigation. While such referrals are relatively uncommon in the SDP context, particularly for matters involving structural compliance deficiencies rather than intentional fraud, the possibility cannot be eliminated.
Fourth, the OIG may expand its investigation beyond the scope of the initial disclosure. Information provided in an SDP submission may prompt the OIG to examine additional arrangements, time periods, or aspects of the disclosing entity's operations that were not the subject of the original disclosure.
Fifth, the SDP process can be lengthy and uncertain. Resolution of an SDP matter typically takes twelve to twenty-four months or longer, during which time the disclosing entity is subject to ongoing uncertainty regarding the outcome, the potential financial exposure, and the possibility of additional government action. This extended period of uncertainty can be disruptive to business operations, management focus, and strategic planning.
Sixth, the filing of an SDP submission with the OIG may trigger obligations under state anti-kickback laws in the states where AHT operates (Massachusetts, Connecticut, Rhode Island, and New Hampshire), each of which has its own anti-kickback or healthcare fraud statutes. The interaction between federal and state disclosure obligations adds an additional layer of complexity to the filing decision.
E. Applicable Penalty Framework
The penalty framework applicable to AKS violations is multi-layered and potentially severe. An understanding of the full range of penalties is essential to the risk-benefit analysis underlying the SDP filing decision.
Criminal Penalties. The AKS is a criminal statute. A conviction for an AKS violation is a felony, punishable by imprisonment of up to ten (10) years, a fine of up to $100,000 for individuals (or $250,000 for organizations under the Alternative Fines Act, 18 U.S.C. § 3571), or both. Criminal prosecution is generally reserved for cases involving intentional, knowing, and willful conduct, and is typically pursued by DOJ rather than the OIG directly. Nevertheless, the OIG's authority to refer SDP matters to DOJ for criminal review is a relevant consideration.
Civil Monetary Penalties. The Civil Monetary Penalties Law ("CMPL"), 42 U.S.C. § 1320a-7a, authorizes the OIG to impose civil monetary penalties of up to $100,000 per item or service involved in an AKS violation (as adjusted for inflation), plus treble damages (i.e., three times the amount of remuneration paid or received). The CMPL's per-violation penalty structure can result in astronomical theoretical exposure when applied on a per-claim or per-item basis, although actual penalties imposed in SDP resolutions and enforcement actions are typically far below the statutory maximum.
Permissive Exclusion. The OIG may impose permissive exclusion from all federal healthcare programs under 42 U.S.C. § 1320a-7(b)(7) for entities that have engaged in conduct that results in an AKS conviction or that is the basis for a CMPL assessment. Exclusion from Medicare and Medicaid would be a devastating consequence for AHT, given that federal healthcare program revenue represents approximately $130.7 million, or 61%, of AHT's total net revenue.
False Claims Act Liability. AKS violations can also give rise to liability under the False Claims Act ("FCA"), 31 U.S.C. §§ 3729–3733. Since the enactment of the Patient Protection and Affordable Care Act in 2010, claims resulting from AKS violations are deemed false claims for purposes of the FCA. FCA penalties include treble damages plus per-claim penalties of $11,000 to $23,000 or more (as adjusted for inflation). The per-claim penalty structure of the FCA can produce aggregate exposure that is orders of magnitude higher than the remuneration at issue in the underlying AKS violation.
Relevance to AHT. Given AHT's $130.7 million in annual Medicare and Medicaid revenue and the significant volume of claims associated with the arrangements under review, the potential penalty exposure under the CMPL and FCA is substantial. While the theoretical maximum penalties are unrealistically high and unlikely to be imposed in practice, the potential for multi-million-dollar settlements and the existential threat of exclusion underscore the seriousness of the AKS compliance issues identified in this self-assessment. The SDP's favorable penalty framework — generally 1.5 times single damages — represents a significant discount relative to the penalties available in a government-initiated enforcement action.
IV. Analysis of Highest-Risk Arrangements
A. Meridian Diagnostics LLC — Per-Scan Facility Access Fee
1. Description of the Arrangement. Pursuant to a services agreement dated March 1, 2021, AHT entered into an arrangement with Meridian Diagnostics LLC ("Meridian"), a limited liability company organized under the laws of Connecticut and located at 88 Trumbull Street, Hartford, Connecticut 06103. Under the agreement, Meridian provides mobile MRI and advanced diagnostic imaging services at four of AHT's clinic locations in Connecticut. Meridian's imaging technologists and equipment are deployed to the AHT clinic sites on a scheduled basis, and AHT provides Meridian with access to designated clinical space, utilities, ancillary support staff (including scheduling coordination and patient check-in), and patient flow infrastructure.
Meridian is owned by Dr. Franklin Osei, a radiologist who serves as managing member and holds a 60% ownership interest, and Gerald Pratt, a non-physician investor who holds the remaining 40% interest. Meridian is separately enrolled as a Medicare provider and bills directly for the professional and technical components of the imaging services it provides at AHT clinic locations.
The compensation structure of the arrangement is as follows: Meridian pays AHT a per-scan facility access fee of $185 for each scan performed at an AHT clinic location. This fee is intended to compensate AHT for the use of clinic space, utilities, and ancillary support provided in connection with each scan. The per-scan fee is the sole form of compensation flowing from Meridian to AHT under the agreement.
In fiscal year 2022, Meridian performed a total of 4,200 scans at AHT clinic locations, resulting in total facility access fee payments from Meridian to AHT of $777,000 (4,200 scans × $185 per scan). During the same period, AHT physicians generated approximately $2.8 million in referrals to Meridian for diagnostic imaging services, representing the professional fees and technical components billed by Meridian to Medicare, Medicaid, and commercial payers for services ordered by AHT physicians.
Counsel to Meridian in connection with the original services agreement and the current restructuring discussions is Thomas Beckett of Linden & Pryor LLP, located at 750 Main Street, Suite 1400, Hartford, Connecticut 06103.
2. AKS Analysis. The Meridian arrangement presents the most significant AKS risk of any arrangement identified in the self-assessment. The core compliance concern is the per-scan fee structure, which means that the compensation paid by Meridian to AHT varies directly with the volume of scans performed at AHT facilities. Because the volume of scans performed at AHT facilities is, in turn, directly correlated with the volume of referrals from AHT physicians to Meridian, the per-scan fee creates a financial incentive for AHT to generate referrals to Meridian: each additional referral that results in a scan generates an additional $185 in facility access fee revenue to AHT.
The AKS prohibits the knowing and willful solicitation, receipt, offer, or payment of remuneration to induce or reward referrals for items or services reimbursable under federal healthcare programs. 42 U.S.C. § 1320a-7b(b). The per-scan fee structure is problematic because it establishes a direct financial nexus between the volume of referrals (from AHT to Meridian) and the compensation paid (from Meridian to AHT). This nexus is precisely the type of volume-based financial incentive that the AKS is designed to prohibit.
Moreover, the referral flow creates a reciprocal dynamic: AHT benefits from the per-scan fees generated by the referral volume, and Meridian benefits from the revenue generated by the referrals themselves. This bilateral financial interdependence amplifies the AKS risk because both parties have financial incentives to maintain and increase the referral volume.
Calderwood & Harkness has evaluated the Meridian arrangement against each of the potentially applicable AKS safe harbors and concludes that no safe harbor is satisfied:
Space Rental Safe Harbor (42 C.F.R. § 1001.952(b)). The space rental safe harbor requires, among other conditions, that the rental charge be "set in advance" and that the aggregate rental charge not take into account the volume or value of any referrals or business otherwise generated between the parties. The per-scan fee of $185 per scan is not "set in advance" in the sense required by the safe harbor because the aggregate compensation varies with the number of scans performed — it is not a fixed periodic payment. The per-scan structure causes the aggregate compensation to fluctuate directly with volume, which is precisely the type of arrangement the safe harbor is designed to exclude.
Equipment Rental Safe Harbor (42 C.F.R. § 1001.952(c)). The equipment rental safe harbor similarly requires fixed, set-in-advance compensation that does not vary with volume. The per-scan fee structure fails this requirement for the same reasons as the space rental safe harbor.
Personal Services and Management Contracts Safe Harbor (42 C.F.R. § 1001.952(d)). This safe harbor is inapplicable because the facility access fee is not compensation for personal services or management services. The fee is compensation for the use of physical space and ancillary support, not for the services of any individual.
No other AKS safe harbor is applicable to the Meridian arrangement as currently structured. The arrangement accordingly falls outside the protection of any recognized safe harbor and must be evaluated under the general AKS prohibition.
3. Intent Analysis. The AKS requires proof that the defendant acted "knowingly and willfully" in soliciting, receiving, offering, or paying remuneration to induce or reward referrals. However, under the "one-purpose test" adopted by the majority of federal circuits, the government need not prove that inducing referrals was the sole or even the primary purpose of the arrangement — it is sufficient to establish that at least one purpose of the remuneration was to induce referrals. See, e.g., United States v. Greber, 760 F.2d 68 (3d Cir. 1985); United States v. McClatchey, 217 F.3d 823 (10th Cir. 2000).
Calderwood & Harkness has found no evidence of an explicit quid pro quo or documented intent to induce referrals in connection with the Meridian arrangement. There are no internal AHT communications, memoranda, or presentations suggesting that the facility access fee was established or maintained for the purpose of encouraging AHT physicians to refer patients to Meridian. Similarly, there is no evidence that AHT physicians were instructed, encouraged, or incentivized to refer to Meridian specifically because of the fee arrangement.
However, the absence of documented intent does not eliminate the AKS risk. The structural correlation between per-scan fees and referral volume creates a strong inference of an improper purpose. The OIG and courts have recognized that arrangements structured in a manner that creates inherent financial incentives for referral generation may satisfy the "one-purpose" test even in the absence of explicit evidence of corrupt intent, because the volume-based compensation structure itself evidences an incentive to refer.
Several additional factors are relevant to the intent analysis. The arrangement was not designed or structured based on legal guidance regarding AKS safe harbor compliance. There is no evidence that AHT obtained a legal opinion regarding the arrangement's compliance with the AKS prior to the current engagement. The arrangement appears to have been established based on business considerations — specifically, the desire to provide patients with convenient access to imaging services at AHT clinic locations — without adequate attention to the regulatory implications of the per-scan fee structure.
As a mitigating factor, Calderwood & Harkness notes that AHT did not initiate the per-scan fee structure. The Meridian arrangement predates the Ridgeline Capital Partners acquisition in January 2021, and the per-scan fee structure was inherited from a pre-existing arrangement. While this does not eliminate AHT's liability — the AKS applies to the ongoing receipt of remuneration regardless of who initiated the arrangement — it does tend to undercut any argument that AHT designed the arrangement with the intent to induce referrals.
4. Estimated Financial Exposure. The period of potential AKS liability for the Meridian arrangement extends from the inception of the current agreement on March 1, 2021, through the present date, a period of approximately twenty-seven (27) months. Calderwood & Harkness estimates the financial exposure as follows:
• FY2022 facility access fee revenue: $777,000 (4,200 scans × $185)
• Estimated FY2021 facility access fee revenue (partial year, approximately 10 months): approximately $600,000
• Estimated CY2023 facility access fee revenue (partial year, through anticipated remediation date): approximately $400,000
• Total estimated facility access fee revenue over liability period: approximately $1,780,000
• Total estimated referral volume from AHT to Meridian over liability period: approximately $7,000,000 or more
Under the CMPL, the OIG could seek penalties of up to $100,000 per item or service involved in the violation. If each scan is treated as a separate violation, the theoretical maximum penalty for FY2022 alone would be 4,200 scans × $100,000 = $420 million. This figure is, of course, astronomical and unrealistic in practice — it is presented solely to illustrate the statutory ceiling and the severity of the potential exposure under a worst-case enforcement scenario.
In the more realistic context of an OIG SDP resolution, penalties would likely be calculated at approximately 1.5 times single damages. Using the facility access fee revenue received by AHT as the measure of single damages, the estimated SDP resolution range is approximately $1.2 million to $2.7 million. Using the referral volume as the measure of single damages — which would yield a substantially higher figure — the exposure would be commensurately greater. Calderwood & Harkness believes the more likely measure in an SDP resolution would be based on the remuneration received by AHT (the facility access fees) rather than the total referral volume.
The risk of permissive exclusion in connection with the Meridian arrangement is assessed as low, particularly in the context of a first-time voluntary disclosure with proactive remediation. However, exclusion cannot be entirely ruled out, and the magnitude of the consequence (loss of access to $130.7 million in federal healthcare program revenue) warrants careful consideration.
5. Assessment. The Meridian per-scan facility access fee arrangement is the highest-risk AKS arrangement identified in the self-assessment. The per-scan fee structure is precisely the type of volume-based compensation that the AKS is designed to address, and the arrangement does not satisfy any applicable safe harbor. The structural incentive for referral generation is clear and direct.
However, several mitigating factors weigh against self-disclosure at this time:
(a) The arrangement was proactively identified through a voluntary compliance review initiated at the board level, without any external trigger.
(b) There is no evidence of actual corrupt intent or an explicit quid pro quo.
(c) The arrangement is being promptly restructured to convert the per-scan facility access fee to a fixed monthly rental at fair market value. A draft restructured agreement has been prepared by Calderwood & Harkness and transmitted to Linden & Pryor LLP (counsel to Meridian) for Meridian's review and comment. The restructured agreement will be designed to satisfy the space rental safe harbor.
(d) No government investigation, subpoena, or inquiry is currently pending with respect to the Meridian arrangement or any other AHT arrangement.
(e) No whistleblower complaint or qui tam action related to the Meridian arrangement is known to AHT or its counsel.
On balance, while the Meridian arrangement presents genuine and significant AKS risk, Calderwood & Harkness concludes that the risk-benefit analysis does not favor self-disclosure at this time, provided that the restructured agreement is executed promptly and the prospective risk is thereby eliminated. The analysis of the Meridian arrangement contributes to, but does not alone determine, the overall SDP filing recommendation set forth in Section IX.
B. Pinnacle Laboratory Services Inc. — No-Cost Lab Interface and CME Sponsorship
1. Description of the Arrangement. AHT is party to a preferred laboratory agreement dated June 15, 2020, with Pinnacle Laboratory Services Inc. ("Pinnacle"), a clinical laboratory company located at 1200 Warwick Avenue, Suite 110, Warwick, Rhode Island 02886 (EIN: 05-6138290). Under the agreement, AHT clinics in Rhode Island and southeastern Massachusetts refer outpatient laboratory testing to Pinnacle as a preferred (though not exclusive) laboratory provider. In fiscal year 2022, the total referral volume from AHT to Pinnacle was approximately $1.65 million, representing the Medicare, Medicaid, and commercial payer reimbursement for laboratory services ordered by AHT physicians and performed by Pinnacle.
The self-assessment has identified three distinct compliance issues within the Pinnacle relationship that, individually and in combination, raise AKS concerns:
(a) No-Cost Electronic Laboratory Interface. Pinnacle provides AHT with an electronic laboratory interface that is fully integrated into AHT's ArborConnect EHR/practice management platform. The interface enables AHT physicians to electronically order laboratory tests from Pinnacle and to receive results directly within the ArborConnect system, eliminating the need for manual order entry, fax-based communication, or separate result review workflows. The interface was developed and is maintained by Pinnacle at Pinnacle's sole cost and expense. AHT pays $0.00 for the interface. Based on market comparables for similar laboratory information system interfaces — including pricing data from AHT's ArborConnect licensing program and from third-party laboratory interface vendors — the estimated fair market value of the interface is approximately $120,000 per year.
(b) CME Sponsorship. In fiscal year 2022, Pinnacle sponsored four (4) continuing medical education ("CME") events for AHT physicians. The aggregate cost of the four events — including speaker fees, venue rental, catering, educational materials, and CME accreditation fees — was $86,000. The events were accredited by an independent ACCME-accredited CME provider and were generally open to AHT physicians. The educational content was not Pinnacle-specific and covered topics of general clinical relevance. However, Pinnacle was the sole funder and sponsor of all four events, and attendance was limited to AHT physicians.
(c) Dr. Karen Ellsworth's Equity Interest. Dr. Karen Ellsworth, a physician who is not employed by or affiliated with AHT, holds a 4.2% passive equity interest in Pinnacle. Dr. Ellsworth is the spouse of AHT Chief Executive Officer Dr. Nathan Ellsworth. Dr. Ellsworth's interest in Pinnacle was acquired in 2018, prior to Dr. Nathan Ellsworth's appointment as AHT CEO and prior to the Ridgeline acquisition. Dr. Ellsworth does not serve as an officer, director, or employee of Pinnacle, does not participate in Pinnacle's management or operations, and receives only proportional distributions based on her ownership percentage.
2. AKS Analysis — No-Cost Lab Interface. The provision of a $120,000-per-year technology interface at no cost to AHT constitutes "remuneration" under the AKS. The AKS defines "remuneration" broadly to include "any kickback, bribe, or rebate" and "transfers of anything of value, directly or indirectly, overtly or covertly, in cash or in kind." 42 U.S.C. § 1320a-7b(b). A $120,000 annual benefit provided at no cost by an entity that receives $1.65 million in annual referrals from AHT unquestionably constitutes a transfer of something of value and falls squarely within the statutory definition of remuneration.
The AKS risk is amplified by the functional characteristics of the lab interface. The interface is not merely a passive benefit; it actively facilitates and streamlines the referral process from AHT to Pinnacle. By integrating Pinnacle's ordering and result reporting capabilities directly into ArborConnect, the interface makes it easier for AHT physicians to order from Pinnacle than from any competing laboratory. This creates a functional lock-in effect: the convenience and workflow efficiency provided by the integrated interface creates a disincentive for AHT physicians to use alternative laboratory providers, even if alternative providers offer comparable pricing or superior services. The lock-in effect is, itself, a form of inducement that reinforces the referral relationship.
Calderwood & Harkness has evaluated the no-cost lab interface against potentially applicable AKS safe harbors:
Electronic Health Records Safe Harbor (42 C.F.R. § 1001.952(x)). This safe harbor, which was originally promulgated in 2006 and extended through December 31, 2021, provided protection for the donation of electronic health records items and services, subject to specified conditions. The safe harbor has since expired and, in any event, imposed several requirements that the Pinnacle interface likely did not satisfy, including requirements regarding cost-sharing (the recipient was generally required to pay at least 15% of the donor's cost), written agreements documenting the arrangement, and limitations on the types of technology covered. There is no evidence that the Pinnacle interface arrangement was structured to satisfy the EHR safe harbor during its effective period.
No Other Applicable Safe Harbor. No other AKS safe harbor clearly applies to the gratuitous provision of technology by a recipient of referrals to a referring entity. The personal services safe harbor is inapplicable because the interface is a technology product, not a personal service. The space rental and equipment rental safe harbors are inapplicable because no rental is involved.
The no-cost lab interface is directly linked to the referral relationship between AHT and Pinnacle. The provision of a $120,000 annual benefit at no cost, by a laboratory that receives $1.65 million in annual referrals from the benefit recipient, in a manner that functionally facilitates and reinforces the referral stream, is a paradigmatic AKS concern.
3. AKS Analysis — CME Sponsorship. Pinnacle's sponsorship of four CME events totaling $86,000 in FY2022 for AHT physicians raises additional AKS concerns regarding remuneration to referral sources. While the funding of physician education is not inherently prohibited by the AKS, the OIG has repeatedly cautioned that CME sponsorships from entities with existing referral relationships should be carefully structured to avoid the appearance of inducements for referrals. See, e.g., OIG Compliance Program Guidance for Pharmaceutical Manufacturers (68 Fed. Reg. 23731, May 5, 2003); OIG Special Advisory Bulletin on Offering Gifts and Other Inducements to Beneficiaries (67 Fed. Reg. 55855, August 30, 2002).
There is no specific CME safe harbor under the AKS. Educational sponsorship by a clinical laboratory that receives referrals from the physicians being educated is a recognized red flag in the OIG's enforcement guidance. The risk is heightened by several factors: (i) the volume of the sponsorship ($86,000 in a single fiscal year) is substantial and far exceeds any incidental or de minimis threshold; (ii) the CME events were funded exclusively by Pinnacle, with no co-sponsorship or independent funding; and (iii) the CME events were limited to AHT physicians, suggesting that the educational benefit was targeted at physicians who are in a position to refer to Pinnacle, rather than at the broader medical community.
Calderwood & Harkness acknowledges certain mitigating factors. The CME events were accredited by an independent ACCME-accredited provider, which suggests that the educational content was independently developed and not controlled by Pinnacle. The educational content was not Pinnacle-specific and covered topics of general clinical relevance. However, the accreditation and content neutrality of the CME events do not eliminate the AKS concern. The economic substance of the arrangement — $86,000 in value transferred from a referral recipient to the referral source — is the relevant consideration under the AKS.
4. AKS Analysis — Dr. Karen Ellsworth's Equity Interest. Dr. Karen Ellsworth's 4.2% passive equity interest in Pinnacle introduces an additional and significant complicating factor to the Pinnacle relationship. Dr. Nathan Ellsworth, as AHT's CEO, has influence — whether direct or indirect — over AHT's referral patterns, laboratory contracting decisions, and preferred vendor relationships. While Dr. Karen Ellsworth is not employed by or affiliated with AHT, the spousal relationship creates a circumstance in which the CEO's household derives a financial benefit from the volume of business referred from AHT to Pinnacle.
The AKS investment safe harbor, 42 C.F.R. § 1001.952(a), provides protection for certain investment interests, subject to specified conditions. Among other requirements, the safe harbor requires that the investment opportunity not be offered to an investor as an inducement to generate business for the entity, and that the investor's returns be proportional to the amount of capital invested (not to the volume or value of referrals). Even if Dr. Karen Ellsworth's investment technically satisfies the investment safe harbor — and Calderwood & Harkness has not concluded that it does — the appearance of a conflict of interest is significant, particularly in light of the other benefits flowing from Pinnacle to AHT (the no-cost lab interface and the CME sponsorship).
The combination of Dr. Karen Ellsworth's equity ownership in Pinnacle, the $120,000-per-year no-cost lab interface, and the $86,000 in annual CME sponsorship creates a pattern that, taken together, could support an inference of inducement. While each element might be viewed in isolation as a moderate-risk compliance issue, the aggregation of these elements within a single referral relationship creates a cumulative risk that is greater than the sum of its parts. The OIG and DOJ have demonstrated a willingness to examine the totality of a financial relationship between a referral source and a referral recipient, rather than evaluating each element in isolation.
5. Estimated Financial Exposure. The period of potential AKS liability for the Pinnacle arrangement extends from the inception of the preferred laboratory agreement on June 15, 2020, through the present date, a period of approximately thirty-six (36) months. Calderwood & Harkness estimates the financial exposure as follows:
• Value of no-cost lab interface over liability period: approximately $360,000 ($120,000 × 3 years)
• Value of CME sponsorship over liability period: approximately $200,000 or more (estimated across multiple fiscal years, based on $86,000 in FY2022 and comparable levels in prior years)
• Total estimated remuneration received by AHT from Pinnacle: approximately $560,000
• Total estimated referral volume from AHT to Pinnacle over liability period: approximately $4.5 million or more
Under the OIG's general SDP resolution framework of 1.5 times single damages, using the remuneration received by AHT as the measure of single damages, the estimated SDP resolution range is approximately $840,000 to $1.2 million. The higher end of this range reflects the possibility that the OIG could treat the full referral volume, or a portion thereof, as the government's loss rather than limiting the damages calculation to the remuneration received.
The CMPL's per-claim penalty structure could produce theoretical maximum exposure that is many multiples of these figures, but such penalties are unrealistic in the SDP context. The risk of permissive exclusion in connection with the Pinnacle arrangement is assessed as low, given the passive nature of the equity interest, the absence of evidence of intentional inducement, and AHT's commitment to voluntary remediation.
6. Assessment. The Pinnacle relationship presents a moderate-to-high AKS risk. The no-cost lab interface is the most significant concern, as it represents $120,000 per year in gratuitous remuneration that is functionally linked to a $1.65 million annual referral stream and that creates a lock-in effect reinforcing the referral relationship. The CME sponsorship and the CEO spousal equity interest amplify the risk by creating additional financial connections between AHT and Pinnacle and by introducing an appearance of conflict of interest.
Several mitigating factors weigh against self-disclosure at this time:
(a) There is no evidence that the preferred laboratory agreement contains explicit referral requirements or minimum volume commitments. AHT physicians retain discretion to order laboratory services from alternative providers.
(b) Dr. Karen Ellsworth's equity interest in Pinnacle is passive, was acquired prior to her spouse's appointment as AHT CEO, and was not provided by Pinnacle as an inducement to AHT or to Dr. Nathan Ellsworth.
(c) AHT is proactively addressing the identified issues. Calderwood & Harkness has prepared a letter to Pinnacle, on AHT's behalf, requesting restructuring of the arrangement to include: (i) conversion of the no-cost lab interface to a license arrangement at fair market value; (ii) separation of CME sponsorship from the referral relationship, including transition to independently funded CME programs or multi-sponsor events; and (iii) formal disclosure and management of the conflict of interest arising from Dr. Karen Ellsworth's equity interest, including potential recusal of Dr. Nathan Ellsworth from laboratory contracting decisions.
On balance, Calderwood & Harkness concludes that the Pinnacle relationship contributes to, but does not alone necessitate, an OIG SDP submission at this time, provided that the restructuring measures are promptly implemented.
C. Above-FMV Medical Director Compensation (38 Arrangements)
1. Description of the Arrangements. AHT maintains a total of thirty-eight (38) independent contractor / medical director arrangements across its network of twenty-three outpatient clinics. These arrangements cover a range of clinical and administrative oversight functions, including quality assurance, peer review, utilization management, staff credentialing, regulatory compliance oversight, and clinical protocol development. The medical directors are independent contractor physicians who also maintain active clinical practices and who are in a position to refer patients to AHT facilities for clinical services.
The annual stipends paid to the thirty-eight medical directors range from a low of $25,000 to a high of $110,000 per year. The aggregate annual medical director compensation across all thirty-eight arrangements is $1,920,000. The mean documented hours of service per month per medical director is 8.4 hours, yielding total annual hours across all thirty-eight arrangements of approximately 3,830.4 hours (38 medical directors × 8.4 hours per month × 12 months). The resulting effective average hourly rate is $501.28 per hour ($1,920,000 ÷ 3,830.4 hours).
The effective average hourly rate of $501.28 per hour has been flagged as above the 90th percentile for multiple physician specialties, including internal medicine, family medicine, cardiology, and orthopedics, based on MGMA and SullivanCotter benchmark data. This finding has been confirmed by preliminary analysis from Northbridge Valuation Advisors LLC (Sandra Kilpatrick, Managing Director), which is in the process of preparing individual FMV opinions for each of the thirty-eight arrangements.
It is important to note that the $501.28 figure is an average across all thirty-eight arrangements. Some individual arrangements may be at or below FMV, while others may substantially exceed it. The distribution of effective hourly rates across the thirty-eight arrangements is analyzed in detail in the Medical Director Compensation FMV and Commercial Reasonableness Analysis memorandum. For purposes of this SDP evaluation, the aggregate and average figures are sufficient to illustrate the systemic nature of the compliance concern.
Three of the thirty-eight arrangements are legacy Lakeview Medical Associates agreements that were assumed by AHT in connection with the August 15, 2022 asset purchase. The stipends under these legacy arrangements are $45,000, $60,000, and $72,000 per year, respectively. These arrangements were not negotiated or set by AHT but were assumed without independent FMV substantiation at the time of the acquisition.
2. AKS Analysis. Compensation paid to physicians who are in a position to refer federal healthcare program patients to the payor, and that exceeds fair market value, constitutes potential "remuneration" under the AKS. The excess compensation — the amount by which the physician's compensation exceeds what would be paid in an arm's-length transaction for comparable services — may be viewed as an inducement for the medical director to refer or to continue referring patients to AHT facilities. This is the fundamental AKS concern presented by the above-FMV medical director compensation.
The personal services and management contracts safe harbor, 42 C.F.R. § 1001.952(d), provides protection for compensation paid under personal services arrangements, subject to several conditions. Among the most relevant conditions are the requirements that:
(i) the aggregate compensation paid to the contractor must be "set in advance";
(ii) the aggregate compensation must be "consistent with fair market value in arms-length transactions"; and
(iii) the aggregate compensation must "not [be] determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties for which payment may be made in whole or in part under Medicare, Medicaid, or other Federal health care programs."
The effective average hourly rate of $501.28 — exceeding the 90th percentile for multiple specialties — raises serious questions about whether the "consistent with fair market value" condition is satisfied. While there is no bright-line FMV threshold in the AKS or its safe harbors, compensation that significantly exceeds published benchmark percentiles is likely to be viewed by the OIG as inconsistent with FMV absent compelling justification, such as unique qualifications, specialized expertise, or extraordinary duties that differentiate the services from those captured by standard benchmarks.
The AKS risk is further compounded by the inadequacy of the documentation supporting many of the thirty-eight arrangements. Calderwood & Harkness's review has revealed that many of the arrangements lack documented duty descriptio